GENERAL CIP QUESTIONS WITH
COMPLETE SOLUTIONS GRADED A+
exception:
, occurs when an overt or implicit threat of harm is intentionally presented by one
person to another in order to obtain compliance.
ongoing exchange of information between the investigator and the subject and
could include, for example, use of question and answer sessions, community
meetings, and videotape presentations.
Investigations in the U.S. complied with FDA regulations 21 CFR 50, 56, and 812.
Investigations outside the U.S. complied with GCP and provide supporting
information.
Don't know?
2 of 161
Term
A double-blinded trial for a new indication is conducted under an
IND comparing two (2) marketed drugs, at twice the approved
prescribed doses. On Day 2, subject 603 had difficulty breathing.
Although it was life-threatening initially, subject 603 was treated and
discharged directly from the emergency department after complete
recovery. On Day 5, subject 20 had a headache, which led to
hospitalization and required blood pressure lowering medications.
These episodes cannot be explained on the basis of the
pharmacological property of either drug or the subjects' medical
histories. The investigator would submit an SAE report for:
Give this one a try later!
, Both of the subjects;
While subject 603 was admitted and discharged from the emergency
department which is not considered meeting the SAE criteria of a
hospitalization, the life-threatening nature of the symptoms does meet SAE
criteria. Subject 20 was hospitalized which is reportable as an SAE
Courtney should share this information with Dr. Brazier and contact Sara at
DrugCo for a determination as to whether the study drug should be
administered to the subject.
(1) The investigator will obtain information through oral or written communication
with the prospective subject or legally authorized representative, or
(2) The investigator will obtain identifiable private information or identifiable
biospecimens by accessing records or stored identifiable biospecimens.
Verify that the correct product was received, the shipment is correct and that the
contents match the description in the protocol.
Inspect the packaging to see if the packaging has been damaged.
Record receipt of the investigational product according to the sponsor's
requirements. Ensure that the date and amount received, and the lot numbers of
the product are recorded on the drug accountability log.
Store the drug according to the instructions in the protocol and on the
packaging.
Ensure that access to the product is controlled.
Don't know?
3 of 161
Term
During the course of administration of an investigational drug, the
following events occurred: On Day 7, subject 603 had an
unexpected stroke that requires hospitalization; On Day 15, subject
415 complained of nausea, vomiting, and headache relieved by
, aspirin; On Day 21, subject 20 has brief dizzy spells upon trying to
stand. Which of these subject's events meets the FDA definition of
"serious" and "unexpected" and would require the sponsor to file an
IND Safety Report with the FDA?
Give this one a try later!
Courtney should share this information with Dr. Brazier and contact Sara at
DrugCo for a determination as to whether the study drug should be
administered to the subject.
Investigations in the U.S. complied with FDA regulations 21 CFR 50, 56, and 812.
Investigations outside the U.S. complied with GCP and provide supporting
information.
Subject 603 only;
The incident for subject 603 meets the FDA definition of "serious" and
"unexpected." The incidents for subjects 20 and 415 do not meet the FDA
definition of "serious."
The study is not intended to be reported to FDA to support a new indication or
support a labeling change.
Don't know?
4 of 161
Term
COMPLETE SOLUTIONS GRADED A+
exception:
, occurs when an overt or implicit threat of harm is intentionally presented by one
person to another in order to obtain compliance.
ongoing exchange of information between the investigator and the subject and
could include, for example, use of question and answer sessions, community
meetings, and videotape presentations.
Investigations in the U.S. complied with FDA regulations 21 CFR 50, 56, and 812.
Investigations outside the U.S. complied with GCP and provide supporting
information.
Don't know?
2 of 161
Term
A double-blinded trial for a new indication is conducted under an
IND comparing two (2) marketed drugs, at twice the approved
prescribed doses. On Day 2, subject 603 had difficulty breathing.
Although it was life-threatening initially, subject 603 was treated and
discharged directly from the emergency department after complete
recovery. On Day 5, subject 20 had a headache, which led to
hospitalization and required blood pressure lowering medications.
These episodes cannot be explained on the basis of the
pharmacological property of either drug or the subjects' medical
histories. The investigator would submit an SAE report for:
Give this one a try later!
, Both of the subjects;
While subject 603 was admitted and discharged from the emergency
department which is not considered meeting the SAE criteria of a
hospitalization, the life-threatening nature of the symptoms does meet SAE
criteria. Subject 20 was hospitalized which is reportable as an SAE
Courtney should share this information with Dr. Brazier and contact Sara at
DrugCo for a determination as to whether the study drug should be
administered to the subject.
(1) The investigator will obtain information through oral or written communication
with the prospective subject or legally authorized representative, or
(2) The investigator will obtain identifiable private information or identifiable
biospecimens by accessing records or stored identifiable biospecimens.
Verify that the correct product was received, the shipment is correct and that the
contents match the description in the protocol.
Inspect the packaging to see if the packaging has been damaged.
Record receipt of the investigational product according to the sponsor's
requirements. Ensure that the date and amount received, and the lot numbers of
the product are recorded on the drug accountability log.
Store the drug according to the instructions in the protocol and on the
packaging.
Ensure that access to the product is controlled.
Don't know?
3 of 161
Term
During the course of administration of an investigational drug, the
following events occurred: On Day 7, subject 603 had an
unexpected stroke that requires hospitalization; On Day 15, subject
415 complained of nausea, vomiting, and headache relieved by
, aspirin; On Day 21, subject 20 has brief dizzy spells upon trying to
stand. Which of these subject's events meets the FDA definition of
"serious" and "unexpected" and would require the sponsor to file an
IND Safety Report with the FDA?
Give this one a try later!
Courtney should share this information with Dr. Brazier and contact Sara at
DrugCo for a determination as to whether the study drug should be
administered to the subject.
Investigations in the U.S. complied with FDA regulations 21 CFR 50, 56, and 812.
Investigations outside the U.S. complied with GCP and provide supporting
information.
Subject 603 only;
The incident for subject 603 meets the FDA definition of "serious" and
"unexpected." The incidents for subjects 20 and 415 do not meet the FDA
definition of "serious."
The study is not intended to be reported to FDA to support a new indication or
support a labeling change.
Don't know?
4 of 161
Term
